STOCK TITAN

[Form 4] Precision BioSciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14–$4.15. Following the transaction, Brown’s direct beneficial ownership increased to 20,565 shares.

No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.

Precision BioSciences (NASDAQ: DTIL) ha presentato un Modulo 4 segnalando che la direttrice Melinda Brown ha acquistato 1.682 azioni ordinarie il 25 giugno 2025 a un prezzo medio ponderato di 4,14–4,15 $. Dopo l'operazione, la proprietà diretta di Brown è aumentata a 20.565 azioni.

Non sono state rivelate altre transazioni né derivative né non derivative, né vendite. Il documento contiene una nota standard che spiega l'intervallo del prezzo medio ponderato. Nessuna casella relativa a un piano di trading 10b5-1 è stata selezionata.

Precision BioSciences (NASDAQ: DTIL) presentó un Formulario 4 informando que la directora Melinda Brown compró 1,682 acciones ordinarias el 25 de junio de 2025 a un precio promedio ponderado de $4.14–$4.15. Tras la transacción, la propiedad directa de Brown aumentó a 20,565 acciones.

No se divulgaron otras transacciones ni derivadas ni no derivadas, y no hubo ventas. La presentación incluye una nota estándar que explica el rango del precio promedio ponderado. No se marcó ninguna casilla relacionada con un plan de trading 10b5-1.

Precision BioSciences (NASDAQ: DTIL)는 이사 Melinda Brown2025년 6월 25일에 가중 평균 가격 $4.14–$4.151,682주의 보통주를 매수했다고 신고하는 Form 4를 제출했습니다. 이 거래 후 Brown의 직접 보유 주식 수는 20,565주로 증가했습니다.

다른 비파생 또는 파생 거래는 공개되지 않았으며, 매도도 없었습니다. 제출 서류에는 가중 평균 가격 범위를 설명하는 표준 각주가 포함되어 있습니다. 10b5-1 거래 계획 박스는 선택되지 않았습니다.

Precision BioSciences (NASDAQ: DTIL) a déposé un formulaire 4 indiquant que la directrice Melinda Brown a acheté 1 682 actions ordinaires le 25 juin 2025 à un prix moyen pondéré de 4,14–4,15 $. Suite à cette transaction, la propriété directe de Brown est passée à 20 565 actions.

Aucune autre transaction, dérivée ou non dérivée, n’a été divulguée, et aucune vente n’a eu lieu. Le dépôt contient une note standard expliquant la fourchette du prix moyen pondéré. Aucune case relative à un plan de négociation 10b5-1 n’a été cochée.

Precision BioSciences (NASDAQ: DTIL) reichte ein Formular 4 ein, in dem berichtet wurde, dass die Direktorin Melinda Brown am 25. Juni 2025 1.682 Stammaktien zu einem gewichteten Durchschnittspreis von erworben hat. Nach der Transaktion erhöhte sich Browns direkte Beteiligung auf 20.565 Aktien.

Es wurden keine weiteren nicht-derivativen oder derivativen Transaktionen offengelegt, und es gab keine Verkäufe. Die Einreichung enthält eine Standardfußnote, die die Preisspanne des gewichteten Durchschnitts erklärt. Kein 10b5-1-Handelsplan wurde angekreuzt.

Positive
  • None.
Negative
  • None.

Precision BioSciences (NASDAQ: DTIL) ha presentato un Modulo 4 segnalando che la direttrice Melinda Brown ha acquistato 1.682 azioni ordinarie il 25 giugno 2025 a un prezzo medio ponderato di 4,14–4,15 $. Dopo l'operazione, la proprietà diretta di Brown è aumentata a 20.565 azioni.

Non sono state rivelate altre transazioni né derivative né non derivative, né vendite. Il documento contiene una nota standard che spiega l'intervallo del prezzo medio ponderato. Nessuna casella relativa a un piano di trading 10b5-1 è stata selezionata.

Precision BioSciences (NASDAQ: DTIL) presentó un Formulario 4 informando que la directora Melinda Brown compró 1,682 acciones ordinarias el 25 de junio de 2025 a un precio promedio ponderado de $4.14–$4.15. Tras la transacción, la propiedad directa de Brown aumentó a 20,565 acciones.

No se divulgaron otras transacciones ni derivadas ni no derivadas, y no hubo ventas. La presentación incluye una nota estándar que explica el rango del precio promedio ponderado. No se marcó ninguna casilla relacionada con un plan de trading 10b5-1.

Precision BioSciences (NASDAQ: DTIL)는 이사 Melinda Brown2025년 6월 25일에 가중 평균 가격 $4.14–$4.151,682주의 보통주를 매수했다고 신고하는 Form 4를 제출했습니다. 이 거래 후 Brown의 직접 보유 주식 수는 20,565주로 증가했습니다.

다른 비파생 또는 파생 거래는 공개되지 않았으며, 매도도 없었습니다. 제출 서류에는 가중 평균 가격 범위를 설명하는 표준 각주가 포함되어 있습니다. 10b5-1 거래 계획 박스는 선택되지 않았습니다.

Precision BioSciences (NASDAQ: DTIL) a déposé un formulaire 4 indiquant que la directrice Melinda Brown a acheté 1 682 actions ordinaires le 25 juin 2025 à un prix moyen pondéré de 4,14–4,15 $. Suite à cette transaction, la propriété directe de Brown est passée à 20 565 actions.

Aucune autre transaction, dérivée ou non dérivée, n’a été divulguée, et aucune vente n’a eu lieu. Le dépôt contient une note standard expliquant la fourchette du prix moyen pondéré. Aucune case relative à un plan de négociation 10b5-1 n’a été cochée.

Precision BioSciences (NASDAQ: DTIL) reichte ein Formular 4 ein, in dem berichtet wurde, dass die Direktorin Melinda Brown am 25. Juni 2025 1.682 Stammaktien zu einem gewichteten Durchschnittspreis von erworben hat. Nach der Transaktion erhöhte sich Browns direkte Beteiligung auf 20.565 Aktien.

Es wurden keine weiteren nicht-derivativen oder derivativen Transaktionen offengelegt, und es gab keine Verkäufe. Die Einreichung enthält eine Standardfußnote, die die Preisspanne des gewichteten Durchschnitts erklärt. Kein 10b5-1-Handelsplan wurde angekreuzt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brown Melinda

(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW STREET, SUITE A-100

(Street)
DURHAM NC 27701

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/25/2025 P 1,682 A $4.14(1) 20,565 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.14 to $4.15. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
Remarks:
/s/ Dario Scimeca, Attorney-in-fact for Melinda Brown 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DTIL shares did director Melinda Brown buy on June 25, 2025?

The Form 4 shows a purchase of 1,682 common shares.

What is Melinda Brown’s total direct ownership after the reported transaction?

After the purchase, Brown now directly owns 20,565 DTIL shares.
Precision Biosciences

NASDAQ:DTIL

DTIL Rankings

DTIL Latest News

DTIL Latest SEC Filings

DTIL Stock Data

50.23M
9.71M
12.23%
50.49%
9.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DURHAM